Vanda Pharmaceuticals (VNDA) shares rose 11% in recent Monday trading after the company rejected a second unsolicited buyout proposal from Cycle Pharmaceuticals for $8 a share.
The offer, received on Sept. 23, is "economically identical to the previously evaluated and rejected indication of interest," and "is another opportunistic attempt to purchase the company's shares at a discount to Vanda's intrinsic value," the company said Monday in a statement.
Cycle Group said Monday in a statement its proposal represents an 80% premium to Vanda's share price at the close of business Friday, compared to a 58% premium on June 5.
Price: 4.9450, Change: +0.5050, Percent Change: +11.3739
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。